Acumen Pharmaceuticals Director Kimberlee Drapkin Receives Equity Awards

Acumen Pharmaceuticals, Inc. (ABOS) director Kimberlee C. Drapkin received significant equity awards on June 3, 2026. The Form 4 filing discloses that Drapkin was granted 35,500 restricted stock units (RSUs) representing a contingent right to receive common stock, which will vest on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, subject to continuous service. Additionally, she received stock options for 53,250 shares with an exercise price of $2.29 per share, expiring June 3, 2036, with the same vesting schedule. Following these transactions, Drapkin holds 48,300 shares of common stock and 53,250 stock options. The awards were granted at $0 cost to the director, which is typical for equity compensation awards to directors. The filing was signed by attorney-in-fact Derek Meisner on June 5, 2026.